Publisher
Springer Science and Business Media LLC
Reference148 articles.
1. Ko, K., Knight, G., Rucker, J. J. & Cleare, A. J. Psychedelics, mystical experience, and therapeutic efficacy: a systematic review. Front. Psychiatry 13, 917199 (2022).
2. Johnson, M. W. in Disruptive Psychopharmacology Vol. 56 (eds Barrett, F. S. & Preller, K. H.) 213–227 (Springer, 2022).
3. Holze, F., Gasser, P., Müller, F., Dolder, P. C. & Liechti, M. E. Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study. Biol. Psychiatry 93, 215–223 (2023).
4. Moreno, F. A., Wiegand, C. B., Taitano, E. K. & Delgado, P. L. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive–compulsive disorder. J. Clin. Psychiatry 67, 1735–1740 (2006).
5. COMPASS Pathways to launchphase 2 trial of COMP360 psilocybin therapy for post-traumatic stress disorder. COMPASS News Archive https://compasspathways.com/trial-comp360-psilocybin-therapy-post-traumatic-stress-disorder/ (2021).
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献